版本:
中国

Lundbeck says Alzheimer's late-stage study fails

Sept 22 Danish drugmaker H Lundbeck A/S said its late-stage study testing an experimental drug to treat mild to moderate Alzheimer's disease failed.

The company said both doses of its drug idalopirdine failed to improve symptoms of the disease measured on a scale called ADAS-cog in the study named Starshine.

Lundbeck added that idalopirdine was safe and well-tolerated. The company was testing the drug in combination with donepezil, a compound that forms the core of Pfizer Inc's Alzheimer's treatment Aricept.

The Copenhagen-based company said both doses of idalopirdine, being developed with Japan's Otsuka Pharmaceutical Co Ltd, also failed to meet the secondary goals of the study.

Lundbeck said two other late-stage studies of its experimental drug would continue as planned and it expected data from the two studies in the first quarter of 2017.

The company's shares closed up about 1 percent at 271.70 Danish crowns. (Reporting by Vidya L Nathan in Bengaluru; Editing by Shounak Dasgupta)

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐